Journal of Clinical Oncology, Vol 15, 1171-1182, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique

H Rubie, O Hartmann, J Michon, D Frappaz, C Coze, P Chastagner, MC Baranzelli, D Plantaz, H Avet-Loiseau, J Benard, O Delattre, M Favrot, MC Peyroulet, A Thyss, Y Perel, C Bergeron, B Courbon-Collet, JP Vannier, J Lemerle and D Sommelet
Unite d'Hemato-Oncologie Pediatrique, Service de Medecine Infantile B, CHU Purpan, Toulouse, France.

PURPOSE: To assess the relevance of N-Myc gene amplification (NMA) as a prognostic factor in localized neuroblastoma (NB) and to evaluate whether less intensive adjuvant treatment is advisable in infants without NMA. PATIENTS AND METHODS: Assessment of NBs included clinical and imaging data to allow tumor-node-metastasis (TNM) staging, biologic determinations (N-Myc gene analysis), and standard histology and work- up to eliminate metastatic spread (metaiodobenzylguanidine [MIBG] scintigraphy and extensive bone marrow staging). Resectability was defined according to imaging findings. Chemotherapy was indicated in children older than 1 year at diagnosis who had postoperative residual disease or lymph node (LN) involvement, in infants with NMA, or as primary treatment in children with an unresectable NB, including dumbbell tumors. Radiotherapy was recommended in children older than 1 who presented with persistent gross residual disease at the end of therapy. RESULTS: Between 1990 and 1994, 316 consecutive children who presented with a localized NB were registered in the NBL 90 study. The median age was 12 months, and 42 patients had dumbbell tumors (13%). NMA was found in 22 of 225 assessable children (10%) and correlated with adverse prognostic indicators such as age older than 1 year, an abdominal primary tumor, a large tumor (T3), and unresectability. Among 186 children who had primary excision, five died of surgery-related complications. Primary chemotherapy was given to 130 patients, which allowed removal of the tumor in all but four. The 5-year overall survival (OS) and event-free survival (EFS) rates were, respectively, 91% and 84% with a median follow-up time of 36 months. The outcome of infants and older children was similar (P = .2). EFS of patients with resectable tumors was slightly better than with unresectable primary tumors (EFS, 89% v 78%; P = .02). In dumbbell NBs, neurologic recovery was achieved in 74% of cases that presented with symptoms, and initial laminectomy was avoided in 75% of children. In a univariate analysis, large tumors, high neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) levels, positive LNs, macroscopic residue, and NMA adversely influenced outcome. In the multivariate analysis, NMA was the most powerful unfavorable predictive indicator: OS and EFS rates for these children were 36% and 32%, compared with 98% and 90% in nonamplified tumors (P < .001). CONCLUSION: Our data confirm the overall good prognosis of localized NBs, even when unresectable. NMA is the most relevant adverse prognostic factor in localized NBs, and more intensive treatment should be investigated in these patients. Prospective studies of other biologic factors are warranted to tailor therapy more accurately. The EFS of children who underwent primary surgery was excellent, and further justifies elimination of adjuvant treatment provided they have no NMA. Despite the elimination of postoperative therapy, infants with non-NMA tumors have an excellent outcome, which suggests that initial chemotherapy can be further reduced in case of unresectable NBs.

This article has been cited by other articles:

				J. Schneiderman, W. B. London, G. M. Brodeur, R. P. Castleberry, A. T. Look, and S. L. Cohn Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group J. Clin. Oncol., February 20, 2008; 26(6): 913 - 918. [Abstract] [Full Text] [PDF]

				M. M. Refaat, S. Z. Idriss, and L. S. Blaszkowsky Case Report: An Unusual Case of Adrenal Neuroblastoma in Pregnancy Oncologist, February 1, 2008; 13(2): 152 - 156. [Abstract] [Full Text] [PDF]

				H. Rubie, J. Chisholm, A. S. Defachelles, B. Morland, C. Munzer, D. Valteau-Couanet, V. Mosseri, C. Bergeron, C. Weston, C. Coze, et al. Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group New Agents Group Study J. Clin. Oncol., November 20, 2006; 24(33): 5259 - 5264. [Abstract] [Full Text] [PDF]

				I.-M. Shih, J. J.-C. Sheu, A. Santillan, K. Nakayama, M. J. Yen, R. E. Bristow, R. Vang, G. Parmigiani, R. J. Kurman, C. G. Trope, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma PNAS, September 27, 2005; 102(39): 14004 - 14009. [Abstract] [Full Text] [PDF]

				M. V. Corrias, L. B. Faulkner, A. Pistorio, C. Rosanda, F. Callea, M. S. L. Piccolo, P. Scaruffi, C. Marchi, L. Lacitignola, M. Occhino, et al. Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different Techniques: Accuracy and Relationship with Clinical Features of Patients Clin. Cancer Res., December 1, 2004; 10(23): 7978 - 7985. [Abstract] [Full Text] [PDF]

				M.-D. Leclair, O. Hartmann, Y. Heloury, L. Fourcade, A. Laprie, F. Mechinaud, C. Munzer, and H. Rubie Localized Pelvic Neuroblastoma: Excellent Survival and Low Morbidity With Tailored Therapy--The 10-Year Experience of the French Society of Pediatric Oncology J. Clin. Oncol., May 1, 2004; 22(9): 1689 - 1695. [Abstract] [Full Text] [PDF]

				I.M. Ambros, J. Benard, M. Boavida, N. Bown, H. Caron, V. Combaret, J. Couturier, C. Darnfors, O. Delattre, J. Freeman-Edward, et al. Quality Assessment of Genetic Markers Used for Therapy Stratification J. Clin. Oncol., June 1, 2003; 21(11): 2077 - 2084. [Abstract] [Full Text] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]

				Q. Wang, G. Hii, S. Shusterman, Y. Mosse, C. L. Winter, C. Guo, H. Zhao, E. Rappaport, M. D. Hogarty, and J. M. Maris ID2 Expression Is not Associated with MYCN Amplification or Expression in Human Neuroblastomas Cancer Res., April 1, 2003; 63(7): 1631 - 1635. [Abstract] [Full Text] [PDF]

				V. Combaret, C. Audoynaud, I. Iacono, M.-C. Favrot, M. Schell, C. Bergeron, and A. Puisieux Circulating MYCN DNA as a Tumor-specific Marker in Neuroblastoma Patients Cancer Res., July 1, 2002; 62(13): 3646 - 3648. [Abstract] [Full Text] [PDF]

				S. Kunwar, G. Mohapatra, A. Bollen, K. R. Lamborn, M. Prados, and B. G. Feuerstein Genetic Subgroups of Anaplastic Astrocytomas Correlate with Patient Age and Survival Cancer Res., October 1, 2001; 61(20): 7683 - 7688. [Abstract] [Full Text] [PDF]

				B. H. Kushner, S. Wolden, M. P. LaQuaglia, K. Kramer, D. Verbel, G. Heller, and N.-K. V. Cheung Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery J. Clin. Oncol., June 1, 2001; 19(11): 2821 - 2828. [Abstract] [Full Text] [PDF]

				A. Valent, J. Benard, B. Clausse, M. Barrois, D. Valteau-Couanet, M.-J. Terrier-Lacombe, B. Spengler, and A. Bernheim In Vivo Elimination of Acentric Double Minutes Containing Amplified MYCN from Neuroblastoma Tumor Cells Through the Formation of Micronuclei Am. J. Pathol., May 1, 2001; 158(5): 1579 - 1584. [Abstract] [Full Text] [PDF]

				C. C. Raggi, M. Maggi, D. Renzi, A. Calabrò, M. L. Bagnoni, P. Scaruffi, G. P. Tonini, M. Pazzagli, B. De Bernardi, G. Bernini, et al. Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3866 - 3873. [Abstract] [Full Text]

				S. U. Goebel, C. Heppner, A. L. Burns, S. J. Marx, A. M. Spiegel, Z. Zhuang, I. A. Lubensky, F. Gibril, R. T. Jensen, and J. Serrano Genotype/Phenotype Correlation of Multiple Endocrine Neoplasia Type 1 Gene Mutations in Sporadic Gastrinomas J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 116 - 123. [Abstract] [Full Text]

				C. C. Raggi, M. L. Bagnoni, G. P. Tonini, M. Maggi, G. Vona, P. Pinzani, K. Mazzocco, B. De Bernardi, M. Pazzagli, and C. Orlando Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System Clin. Chem., November 1, 1999; 45(11): 1918 - 1924. [Abstract] [Full Text] [PDF]

				K. Kawa, N. Ohnuma, M. Kaneko, K. Yamamoto, T. Etoh, H. Mugishima, M. Ohhira, J. Yokoyama, F. Bessho, T. Honna, et al. Long-Term Survivors of Advanced Neuroblastoma With MYCN Amplification: A Report of 19 Patients Surviving Disease-Free for More Than 66 Months J. Clin. Oncol., October 1, 1999; 17(10): 3216 - 3220. [Abstract] [Full Text] [PDF]

				S. L. Cohn Diagnosis and Classification of the Small Round-Cell Tumors of Childhood Am. J. Pathol., July 1, 1999; 155(1): 11 - 15. [Full Text] [PDF]

				J. A. Ross and S. M. Davies Screening for Neuroblastoma: Progress and Pitfalls Cancer Epidemiol. Biomarkers Prev., February 1, 1999; 8(2): 189 - 194. [Full Text]